Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.

Gori, S; Montemurro, F; Spazzapan, S; Metro, G; Foglietta, J; Bisagni, G; Ferzi, A; Silva, R R; Gamucci, T; Clavarezza, M; Stocchi, L; Fabi, A; Cognetti, F; Torrisi, E; Crivellari, D

Gori, S; Montemurro, F; Spazzapan, S; Metro, G; Foglietta, J; Bisagni, G; Ferzi, A; Silva, R R; Gamucci, T; Clavarezza, M; Stocchi, L; Fabi, A; Cognetti, F; Torrisi, E; Crivellari, D.

Affiliation

Gori S; Department of Medical Oncology, S. Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia. stefania.gori@tin.it

Ann Oncol ; 23(6): 1436-41, 2012 Jun.

Article in En | MEDLINE | ID: mdl-22039084

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Quinazolines/pharmacology; Receptor, ErbB-2/metabolism; Adult; Aged; Aged, 80 and over; Breast Neoplasms/metabolism; Breast Neoplasms/mortality; Breast Neoplasms/pathology; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines/therapeutic use; Retrospective Studies; Trastuzumab; Treatment Failure

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google